Whole-genome Sequencing Reveals KRTAP1-1 As a Novel Genetic Variant Associated with Antidepressant Treatment Outcomes

Overview

Journal Sci Rep

Specialty Science

Date 2021 Feb 26

PMID 33633223

Citations 3

Authors

Jong-Ho Park

Shinn-Won Lim

Woojae Myung

Inho Park

Hyeok-Jae Jang

Seonwoo Kim

Min-Soo Lee

Hun Soo Chang

DongHo Yum

Yeon-Lim Suh

Jong-Won Kim

Doh Kwan Kim

Affiliations

Soon will be listed here.

Abstract

Achieving remission following initial antidepressant therapy in patients with major depressive disorder (MDD) is an important clinical result. Making predictions based on genetic markers holds promise for improving the remission rate. However, genetic variants found in previous genetic studies do not provide robust evidence to aid pharmacogenetic decision-making in clinical settings. Thus, the objective of this study was to perform whole-genome sequencing (WGS) using genomic DNA to identify genetic variants associated with the treatment outcomes of selective serotonin reuptake inhibitors (SSRIs). We performed WGS on 100 patients with MDD who were treated with escitalopram (discovery set: 36 remitted and 64 non-remitted). The findings were applied to an additional 553 patients with MDD who were treated with SSRIs (replication set: 185 remitted and 368 non-remitted). A novel loss-of-function variant (rs3213755) in keratin-associated protein 1-1 (KRTAP1-1) was identified in this study. This rs3213755 variant was significantly associated with remission following antidepressant treatment (p = 0.0184, OR 3.09, 95% confidence interval [CI] 1.22-7.80 in the discovery set; p = 0.00269, OR 1.75, 95% CI 1.22-2.53 in the replication set). Moreover, the expression level of KRTAP1-1 in surgically resected human temporal lobe samples was significantly associated with the rs3213755 genotype. WGS studies on a larger sample size in various ethnic groups are needed to investigate genetic markers useful in the pharmacogenetic prediction of remission following antidepressant treatment.

Citing Articles

Sex Influences Genetic Susceptibility to Depression-Like Behaviors in Chronic Unpredictable Mild Stress-Exposed Wistar Rats.

Jimoh-Abdulghaffaar H, Joel I, Jimoh O, Ganiyu K, Alatiba T, Ogunyomi V Mol Neurobiol. 2024; 62(2):1591-1604.

PMID: 39012445 DOI: 10.1007/s12035-024-04348-5.

Exploring mood disorders and treatment options using human stem cells.

Hudock A, Leal Z, Sharma A, Mei A, Santos R, Marchetto M Genet Mol Biol. 2024; 47Suppl 1(Suppl 1):e20230305.

PMID: 38954533 PMC: 11223183. DOI: 10.1590/1678-4685-GMB-2023-0305.

Integration of whole-exome sequencing and structural neuroimaging analysis in major depressive disorder: a joint study.

Oh E, Han K, Kim A, Kang Y, Tae W, Han M Transl Psychiatry. 2024; 14(1):141.

PMID: 38461185 PMC: 10924915. DOI: 10.1038/s41398-024-02849-4.

References

Kato M, Serretti A . Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2008; 15(5):473-500. DOI: 10.1038/mp.2008.116. View

Karczewski K, Francioli L, Tiao G, Cummings B, Alfoldi J, Wang Q . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443. PMC: 7334197. DOI: 10.1038/s41586-020-2308-7. View

Chang C, Chow C, Tellier L, Vattikuti S, Purcell S, Lee J . Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015; 4:7. PMC: 4342193. DOI: 10.1186/s13742-015-0047-8. View

Wang K, Li M, Hakonarson H . ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164. PMC: 2938201. DOI: 10.1093/nar/gkq603. View

Hennings J, Owashi T, Binder E, Horstmann S, Menke A, Kloiber S . Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res. 2008; 43(3):215-29. DOI: 10.1016/j.jpsychires.2008.05.002. View

Sheldrick A, Camara S, Ilieva M, Riederer P, Michel T . Brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) levels in post-mortem brain tissue from patients with depression compared to healthy individuals - a proof of concept study. Eur Psychiatry. 2017; 46:65-71. DOI: 10.1016/j.eurpsy.2017.06.009. View

Fabbri C, Montgomery S, Lewis C, Serretti A . Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment. Int Clin Psychopharmacol. 2020; 35(5):233-242. PMC: 7390499. DOI: 10.1097/YIC.0000000000000305. View

Tansey K, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A . Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 2012; 73(7):679-82. DOI: 10.1016/j.biopsych.2012.10.030. View

Gibbons R, Hur K, Brown C, Davis J, Mann J . Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012; 69(6):572-9. PMC: 3371295. DOI: 10.1001/archgenpsychiatry.2011.2044. View

10.

Myung W, Kim J, Lim S, Shim S, Won H, Kim S . A genome-wide association study of antidepressant response in Koreans. Transl Psychiatry. 2015; 5:e672. PMC: 5115712. DOI: 10.1038/tp.2015.173. View

11.

OReilly R, Bogue L, Singh S . Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry. 1994; 36(7):467-71. DOI: 10.1016/0006-3223(94)90642-4. View

12.

Kang H, Kim K, Yoo K, Park Y, Kim J, Kim S . Genetic Markers for Later Remission in Response to Early Improvement of Antidepressants. Int J Mol Sci. 2020; 21(14). PMC: 7402334. DOI: 10.3390/ijms21144884. View

13.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

14.

Biernacka J, Sangkuhl K, Jenkins G, Whaley R, Barman P, Batzler A . The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry. 2016; 6(11):e937. PMC: 5314112. DOI: 10.1038/tp.2016.187. View

15.

Glicksberg B, Amadori L, Akers N, Sukhavasi K, Franzen O, Li L . Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits. BMC Med Genomics. 2019; 12(Suppl 6):108. PMC: 6657044. DOI: 10.1186/s12920-019-0542-3. View

16.

Tansey K, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D . Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med. 2012; 9(10):e1001326. PMC: 3472989. DOI: 10.1371/journal.pmed.1001326. View

17.

Zhang X, Gainetdinov R, Beaulieu J, Sotnikova T, Burch L, Williams R . Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron. 2005; 45(1):11-6. DOI: 10.1016/j.neuron.2004.12.014. View

18.

Franchini L, Serretti A, Gasperini M, Smeraldi E . Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res. 1998; 32(5):255-9. DOI: 10.1016/S0022-3956(98)00004-1. View

19.

Lim S, Won H, Kim H, Myung W, Kim S, Kim K . Genetic prediction of antidepressant drug response and nonresponse in Korean patients. PLoS One. 2014; 9(9):e107098. PMC: 4166419. DOI: 10.1371/journal.pone.0107098. View

20.

Kennedy S, Lam R, McIntyre R, Tourjman S, Bhat V, Blier P . Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016; 61(9):540-60. PMC: 4994790. DOI: 10.1177/0706743716659417. View